Lead Product(s): Botulinum toxin type A
Therapeutic Area: Musculoskeletal Product Name: Dysport
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Livogiva
Highest Development Status: Approved Product Type: Peptide
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2020
Adalvo recently entered into a commercialization agreement with a multinational pharmaceutical company to commercialize PF708, upon receipt of marketing authorization, in certain countries in Latin America.